Compare EVC & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | VRXA |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 390.3M |
| IPO Year | 2000 | N/A |
| Metric | EVC | VRXA |
|---|---|---|
| Price | $11.59 | $2.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ 47.59 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $536,034,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $84.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.95 | $1.70 |
| 52 Week High | $13.74 | $4.50 |
| Indicator | EVC | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 27.70 |
| Support Level | $2.75 | $1.88 |
| Resistance Level | $13.74 | $3.49 |
| Average True Range (ATR) | 0.88 | 0.46 |
| MACD | -0.23 | 0.00 |
| Stochastic Oscillator | 28.95 | 21.09 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.